{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-363695","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-08-24T20:43:10+00:00","discovered_at":"2026-08-24T20:44:01.572693+00:00","generated_at":"2026-08-24T20:44:06.156018+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tempest CFO Justin Trojanowski resigns Sept 1; Nicholas Rossettos appointed","bullets":["Justin Trojanowski resigns as Principal Financial/Accounting Officer effective Sept 1, 2026.","Nicholas Rossettos named CFO, Principal Financial & Accounting Officer, Treasurer, Secretary effective Sept 1.","Rossettos, 60, is a CPA with 30+ years; prior fractional CFO at Charles River CFO and CFO of Egenix.","He was Interim CFO at Sernova Corp (TSX: SVA) Mar-Oct 2024 and advisor to TransCode (RNAZ) since Apr 2025.","No family relationships or 404(a) transactions disclosed; standard indemnification agreement entered."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-363695","json":"https://secwatch.observer/filing/0001193125-26-363695.json","markdown":"https://secwatch.observer/filing/0001193125-26-363695.md","text":"https://secwatch.observer/filing/0001193125-26-363695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526363695/0001193125-26-363695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526363695/d152818d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-24T20:44:06.156018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05f59683dc","claim":"Justin Trojanowski departed as Principal Financial Officer and Principal Accounting Officer at Tempest Therapeutics, Inc..","evidence_excerpt":"On August 18, 2026, Mr. Justin Trojanowski notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his positions as Principal Financial Officer and Principal Accounting Officer of the Company, and from any and all other positions he holds with the Company, effective as of September 1, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526363695/0001193125-26-363695-index.htm","confidence":0.97,"family_label":"Executive change","details":[{"label":"Action","value":"resign"},{"label":"Role","value":"Principal Financial Officer and Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"187a5121a3","claim":"Nicholas Rossettos was appointed as Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary at Tempest Therapeutics, Inc..","evidence_excerpt":"Effective September 1, 2026, the Board of Directors of the Company (the “Board”) appointed Mr. Nicholas Rossettos as Chief Financial Officer Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526363695/0001193125-26-363695-index.htm","confidence":0.97,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}